We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The European Medicines Agency has recommended that three medicines manufactured by Pharmaceuticals International Inc. (PII) no longer be available in the EU due to possible cross-contamination. Read More
A year from now, each drug product processed and moved through the U.S. supply chain could have its own unique identifier under the Drug Supply Security Act, FDA and industry officials said at a meeting Monday. Read More
The FDA encouraged additional development in topical treatments for head lice infestation, especially in pediatric populations, due to the genetic resistance to the most common treatments. Read More
The DEA has reduced the amount of Schedule II opiate and opioid medications that can be manufactured in the U.S. next year by at least 25 percent. Read More
A European Parliament committee is proposing that the European Commission promote transparency in private research to foster better access to medicines across the EU. Read More
The FDA intends to clarify its expectations for demonstrating the interchangeability of biosimilars with reference products, an FDA official said. Read More
Novartis will pay more than $35 million to settle off-label promotion charges when the company marketed its eczema cream, Elidel, for use on infants. Read More